Zydus Cadila is learnt to have submitted additional data related to immunogenicity and safety to India's drug regulator, reported news agency ANI quoting sources.
The Drug Controller General of India (DCGI) had earlier asked the Ahmedabad-based firm to return with more data on its Zycov-D.
The regulator's Subject Expert Committee (SEC) will examine the additional data and decide on granting the emergency use authorisation (EUA) based on it.
Previously, the ANI had reported that a continuous and rolling review of data was being undertaken and final approval would take a few more days. Approval for Zydus Cadila The Ahmedabad-based pharmaceutical firm had on 1 July applied for emergency use authorization of its ZyCoV-D three-dose